Literature DB >> 1389026

Efficacy of tianeptine in comparative trials versus reference antidepressants. An overview.

J D Guelfi1.   

Abstract

The clinical properties of tianeptine have been assessed in double-blind controlled studies, which involved depressed patients fulfilling DSM-III criteria for either major depression--single episode or recurrent (without melancholia and psychotic features)--or dysthymic disorder--with or without an additional diagnosis of alcohol abuse or dependence. Five studies have compared tianeptine with reference antidepressants: its efficacy has been found to be similar to that of amitriptyline in depressed out-patients. However, these data need to be confirmed by other controlled trials v. reference drugs and by at least two placebo-controlled studies. Tianeptine does not induce sleep disorders, anticholinergic effects, or modifications of cardiovascular variables or biological parameters (renal, haematological, or hepatic). After the end of treatment, the only signs of withdrawal have been some disturbances of sleep.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1389026

Source DB:  PubMed          Journal:  Br J Psychiatry Suppl        ISSN: 0960-5371


  3 in total

1.  Comparative pharmacodynamic studies with the novel serotonin uptake-enhancing tianeptine and -inhibiting fluvoxamine utilizing EEG mapping and psychometry.

Authors:  B Saletu; J Grünberger; P Anderer; L Linzmayer; G Zyhlarz
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

2.  Effect of prenatal exposure to tianeptine on different neurotransmitter receptors and 5-HT-stimulated inositol phosphate formation in rat brain.

Authors:  G Romero; E Toscano; D Montero; M C De Felipe; J Del Rio
Journal:  J Neural Transm Gen Sect       Date:  1992

Review 3.  Tianeptine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depression and coexisting anxiety and depression.

Authors:  M I Wilde; P Benfield
Journal:  Drugs       Date:  1995-03       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.